TruCulture System Proves Superior Reproducibility Over PBMCs

Standardized whole blood stimulation system proves superior reproducibility over PBMCs

A new paper on improved methods for monitoring differential immune response activation was published in Volume 183 of the journal Clinical Immunology. Researchers report on a multi-center study in seven FOCIS Centers of Excellence to directly compare whole blood syringe-based system, TruCulture, to the current method of isolation of PBMCs for immunomonitoring.

To compare intra and inter-center variability between PBMC and TruCulture stimulation, the blood of 152 healthy donors was both stimulated in whole blood assay and after isolation of PBMC, across multiple centers. Following exposure to LPS, anti-CD3/anti-CD28, or media alone, samples were analyzed using multi-analyte profiling (MAP) for 55 proteins at Myriad RBM’s CLIA-certified laboratory. Focusing on analytes that were induced in both TruCulture and PMBC stimulation, further analysis was based on the 35 commonly induced proteins.

Read More

Inflammatory Cytokines as Potential Biomarker for Pain Intensity

Biomarkers for pain assessment are needed for more accurate pain therapy treatment in patients unable to reliably self-report their circumstances such as patients with dementia, intubated patients, and infants. The authors of a study recently published in Biomarkers in Medicine, Soluble intercellular adhesion molecule-1: a potential biomarker for pain intensity in chronic pain patients, hypothesized that pain intensity might be assessable using inflammatory molecules measurable in serum.

Read More

Human Cytokine Testing on Cell Culture Supernatant for SPHEROIDS project

3D Growth of Endothelial Cells During ISS Space Mission – The SPHEROIDS Project

The April 2017 issue of Biomaterials reports on an automated cell culture unit that was developed for the SpaceX CRS-ISS space mission that resulted in three dimensional growth of human endothelial cells in microgravity.

A spaceflight to the International Space Station, carried out in April – May 2016, included a study to examine endothelial cell (EC) behavior in respect to cellular proliferation and apoptosis under spaceflight conditions to examine the gravity dependency of EC tube formation.

Read More

Phase I Clinical Results from FR104, a mAb Specific to CD28

Researchers led by Bernard Vanove of OSE Immunotherapeutics report in the December 7, 2016 issue of the Journal of Immunology on the first-in-human study of FR1041. OSE and collaborators at the University of Nantes and Janssen conducted a detailed phase I evaluation of safety, pharmacokinetics, pharmacodynamics and potency of FR104 in healthy volunteers.

Read More

IL-10 (AM0010) phase I trial offers novel mechanism for immune-oncology drugs in solid tumors

More commonly known as an inhibitory cytokine, high doses of IL-10 have been shown to lead to the activation and survival of antigen stimulated CD8 T cells. According to a study published in the Journal of Clinical Oncology, the investigators in this first-in-human, phase 1 clinical trial of IL-10 (AM0010), demonstrate antitumor activity and therapy tolerability in a pretreated population.  The primary endpoint of the study was to establish safety, tolerability and the maximum tolerated dose.  This goal appears to have been met, with a low incidence of adverse events, most of which were temporary or reversible.  The dose-escalation study was followed by a renal cell cancer dose-expansion cohort.

Read More

TruCulture and Gene Expression Profiling Characterizes Immune Responses in Landmark Study Led by Institut Pasteur

Published in the September 6, 2016 issue of Cell Reports, Standardized Whole-Blood Transcriptional Profiling Enables the Deconvolution of Complex Induced Immune Responses describes the use of the Myriad RBM TruCulture® platform for standardized ex vivo immune stimulation and a high-throughput method for gene expression profiling to explore immune variance within a population.
Read More

Use of biomarkers to guide immunotherapy drug development

VentiRx, the developers of motolimod, a TLR8 agonist, have published preclinical and clinical results that indicate effective immune system stimulation in human whole blood cultures, non-human primates, healthy subjects, and late-stage cancer patients. Immune system stimulation in all of these settings is dose-dependent, characterized by similar biomarkers, and consistent with stimulation via the TLR8 pathway. The rapid translation and development of motolimod clearly benefited from the use of standardized immune monitoring systems and validated biomarker assays.

View Paper »

1 2